U.S. market Closed. Opens in 12 hours

HAE | Haemonetics Corporation Stock Fundamentals

(Stock Exchange: NYSE)
Analyzing fundamentals for HAE we got that it has average fundamentals where Valuation is considered to be fairly valued, Profitability is unacceptably poor, Growth is good and Health is strong.

Valuation (57%)

Company Industry
P/E Ratio (TTM) 33.53 51.65
PEG Ratio (TTM) 4.21 3.84
P/S Ratio (TTM) 2.90 12.48
P/B Ratio (TTM) 4.25 6.59
P/FCF Ratio (TTM) 53.04 328.37
Price to 5YR AVG Earnings Ratio 44.38 113.80
Price to 5YR AVG FCF Ratio 32.86 86.86

Profitability (30%)

Company Industry
ROA (TTM) 4.52% 6.88%
ROE (TTM) 12.41% 12.83%
Net Profit Margin (TTM) 8.61% 2.60%
ROIC 5YR AVG 9.27% 11.03%

Growth (67%)

4QTR AVG 3YR AVG 5YR AVG
EPS 9.76% -47.30% -27.94%
Revenue 1.98% 6.61% 6.37%
Net Income 9.93% 41.49% 25.27%
Cash Flow 3,035.72% 28.54% 10.43%

Health (63%)

Company Industry
Current Ratio (TTM) 3.76 3.37
Quick Ratio (TTM) 2.33 2.56
D/E Ratio (TTM) 1.35 0.39
Interest Coverage (TTM) 9.88 28.02
Piotroski F-Score 6 6
Altman Z-Score 2.71 22.94
LTL to 5YR AVG FCF 6.77 4.38
Shares Outstanding Growth 5YR AVG -19.89% 2.71%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙